sorafenib has been researched along with reparixin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (reparixin) | Trials (reparixin) | Recent Studies (post-2010) (reparixin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 70 | 4 | 48 |
| Protein | Taxonomy | sorafenib (IC50) | reparixin (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.0031 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cetin-Atalay, R; Kahraman, DC; Kahraman, T | 1 |
1 other study(ies) available for sorafenib and reparixin
| Article | Year |
|---|---|
Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Interleukin-8; Liver Neoplasms; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2019 |